Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 219

1.

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.

Lee S, Mullin R, Blazawski J, Coleman CI.

PLoS One. 2012;7(10):e47473. doi: 10.1371/journal.pone.0047473. Epub 2012 Oct 9.

PMID:
23056642
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.

Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):472-9. doi: 10.1161/CIRCOUTCOMES.112.965251. Epub 2012 Jun 26.

PMID:
22740012
[PubMed - indexed for MEDLINE]
Free Article
3.

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

Kamel H, Easton JD, Johnston SC, Kim AS.

Neurology. 2012 Oct 2;79(14):1428-34. doi: 10.1212/WNL.0b013e31826d5fe8. Epub 2012 Sep 19.

PMID:
22993279
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

PMID:
23549134
[PubMed - indexed for MEDLINE]
Free Article
5.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

PMID:
24508420
[PubMed - indexed for MEDLINE]
Free Article
6.

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.

Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI.

Am J Cardiol. 2012 Sep 15;110(6):845-51. doi: 10.1016/j.amjcard.2012.05.011. Epub 2012 May 30.

PMID:
22651881
[PubMed - indexed for MEDLINE]
7.

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.

Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23.

PMID:
23796283
[PubMed - indexed for MEDLINE]
8.

[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].

Rudakova AV, Tatarskiĭ BA.

Kardiologiia. 2014;54(7):43-52. Russian.

PMID:
25177813
[PubMed - indexed for MEDLINE]
9.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
[PubMed - indexed for MEDLINE]
10.

Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.

Amin A, Stokes M, Wu N, Gatt E, Makenbaeva D, Wiederkehr D, Boulanger L.

J Med Econ. 2013 Oct;16(10):1193-202. doi: 10.3111/13696998.2013.828064. Epub 2013 Aug 7.

PMID:
23883416
[PubMed - indexed for MEDLINE]
11.

Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.

Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, Shrank WH, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):724-31. doi: 10.1161/CIRCOUTCOMES.113.000661. Epub 2013 Nov 12.

PMID:
24221832
[PubMed - indexed for MEDLINE]
Free Article
12.

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.

Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.

J Med Econ. 2012;15(4):776-85. doi: 10.3111/13696998.2012.680555. Epub 2012 Apr 13.

PMID:
22449118
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

PMID:
22308255
[PubMed - indexed for MEDLINE]
Free Article
14.

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.

Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW.

Am J Cardiol. 2012 Apr 1;109(7):1020-5. doi: 10.1016/j.amjcard.2011.11.034. Epub 2012 Jan 3.

PMID:
22221944
[PubMed - indexed for MEDLINE]
15.

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.

Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.

J Med Econ. 2013 Sep;16(9):1163-8. doi: 10.3111/13696998.2013.826664. Epub 2013 Aug 8.

PMID:
23869941
[PubMed - indexed for MEDLINE]
16.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
[PubMed - indexed for MEDLINE]
17.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

PMID:
22787066
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Apixaban versus warfarin in patients with atrial fibrillation.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators.

N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.

PMID:
21870978
[PubMed - indexed for MEDLINE]
Free Article
19.

Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.

Yates SW.

Hosp Pract (1995). 2011 Oct;39(4):7-16. doi: 10.3810/hp.2011.10.918. Review.

PMID:
22056819
[PubMed - indexed for MEDLINE]
20.

The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.

Sullivan PW, Arant TW, Ellis SL, Ulrich H.

Pharmacoeconomics. 2006;24(10):1021-33.

PMID:
17002484
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk